stockrow
Saturday 7 November 2026
Export TYRA’s income statement to Excel — free account
Tyra Biosciences, Inc.
TYRA Healthcare Biotechnology
- EPS
- −46.8%
- Free cash flow
- −31.3%
Quarter to June 2026, against a year earlier
21.09
0.20
+0.96%
Follow TYRA
Alert me
Tyra Biosciences, Inc. (TYRA) P/E ratio
Tyra Biosciences, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| OCUL Ocular Therapeutix, Inc. compare | n/m |
| QURE uniQure N.V. compare | n/m |
| KRSA Korsana Biosciences, Inc. compare | n/m |
| TYRA Tyra Biosciences, Inc. | n/m |
| NUVB Nuvation Bio Inc. compare | n/m |
| IMCR Immunocore Holdings PLC Sponsored ADR compare | n/m |
| PGEN Precigen, Inc. compare | 60.3× |
| AAPG Ascentage Pharma Group International - Unsponsored ADR compare | — |
| ADRX ADARx Pharmaceuticals, Inc. compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)